BIOTECH MARKET RESEARCH $ALLK | Ep. 550

Allakos

Mark your calendars—Allakos (ALLK) is gearing up to deliver a significant update! Phase 1 data for AK006 in Chronic Spontaneous Urticaria (CSU) is on the horizon. With the market buzzing and options pricing signaling an implied volatility of +/- 275%, the stakes are high for this potential first-in-class therapy targeting an underserved patient population. Stay tuned—this could be a game-changing milestone for Allakos and those living with CSU!

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: Phase 1 data for AK006 in Chronic Spontaneous Urticaria (CSU)

DATE: Early 2025

IMPLIED VOLATILITY: +/- 275%

BACKGROUND: